Behjat Moayedi

422 total citations
13 papers, 348 citations indexed

About

Behjat Moayedi is a scholar working on Pulmonary and Respiratory Medicine, Pharmacology and Genetics. According to data from OpenAlex, Behjat Moayedi has authored 13 papers receiving a total of 348 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 8 papers in Pharmacology and 7 papers in Genetics. Recurrent topics in Behjat Moayedi's work include Drug-Induced Hepatotoxicity and Protection (8 papers), Silymarin and Mushroom Poisoning (8 papers) and Hemoglobinopathies and Related Disorders (7 papers). Behjat Moayedi is often cited by papers focused on Drug-Induced Hepatotoxicity and Protection (8 papers), Silymarin and Mushroom Poisoning (8 papers) and Hemoglobinopathies and Related Disorders (7 papers). Behjat Moayedi collaborates with scholars based in Iran, United States and Canada. Behjat Moayedi's co-authors include Marjan Gharagozloo, Nafiseh Esmaeil, Mohammad Reza Maracy, Zahra Amirghofran, Abbas Jafarian‐Dehkordi, Hamid Hoorfar, Seyed Ebrahim Sajjadi, Maryam Zakerinia, Mehran Karimi and Mehrdad Hamidi and has published in prestigious journals such as SHILAP Revista de lepidopterología, International Immunopharmacology and Immunology Letters.

In The Last Decade

Behjat Moayedi

12 papers receiving 329 citations

Peers

Behjat Moayedi
Lijun Liu China
Fera Y. Goh Singapore
Lisa Lih-Brody United States
Bahar Akkaya Türkiye
Jie Shao United States
Lijun Liu China
Behjat Moayedi
Citations per year, relative to Behjat Moayedi Behjat Moayedi (= 1×) peers Lijun Liu

Countries citing papers authored by Behjat Moayedi

Since Specialization
Citations

This map shows the geographic impact of Behjat Moayedi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Behjat Moayedi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Behjat Moayedi more than expected).

Fields of papers citing papers by Behjat Moayedi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Behjat Moayedi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Behjat Moayedi. The network helps show where Behjat Moayedi may publish in the future.

Co-authorship network of co-authors of Behjat Moayedi

This figure shows the co-authorship network connecting the top 25 collaborators of Behjat Moayedi. A scholar is included among the top collaborators of Behjat Moayedi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Behjat Moayedi. Behjat Moayedi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Esmaeil, Nafiseh, et al.. (2022). Therapeutic potential of silymarin as a natural iron‐chelating agent in β‐thalassemia intermedia. SHILAP Revista de lepidopterología. 10(1). e05293–e05293. 6 indexed citations
2.
Shaygannejad, Vahid, et al.. (2021). Significant immunomodulatory and hepatoprotective impacts of Silymarin in MS patients: A double-blind placebo-controlled clinical trial. International Immunopharmacology. 97. 107715–107715. 8 indexed citations
3.
Esmaeil, Nafiseh, et al.. (2017). Silymarin impacts on immune system as an immunomodulator: One key for many locks. International Immunopharmacology. 50. 194–201. 100 indexed citations
4.
Alebouyeh, M., et al.. (2015). Preparation of Immunotoxin Herceptin-Botulinum and Killing Effects on Two Breast Cancer Cell Lines. Asian Pacific Journal of Cancer Prevention. 16(14). 5977–5981. 22 indexed citations
5.
Gharagozloo, Marjan, et al.. (2014). Serum levels of TGFβ, IL-10, IL-17, and IL-23 cytokines in β-thalassemia major patients: the impact of silymarin therapy. Immunopharmacology and Immunotoxicology. 36(4). 271–274. 28 indexed citations
6.
Alebouyeh, M., et al.. (2014). Study of the Effect of Silymarin on Viability of Breast Cancer Cell Lines. 3(3). 100–105. 6 indexed citations
7.
Esmaeil, Nafiseh, Behjat Moayedi, Marjan Gharagozloo, & Mohammad Reza Maracy. (2013). Elevated Serum Levels of Cell Death Circulating Biomarkers, M30 and M65, In Patients with β-Thalassemia Major. Hemoglobin. 37(4). 404–410.
8.
Moayedi, Behjat, et al.. (2012). Therapeutic effects of deferoxamine and silymarin versus deferoxamine alone in β-thalassemia major based on findings of liver MRI. Journal of Research in Medical Sciences. 17. 5 indexed citations
9.
Moayedi, Behjat, et al.. (2012). A randomized double‐blind, placebo‐controlled study of therapeutic effects of silymarin in β‐thalassemia major patients receiving desferrioxamine. European Journal Of Haematology. 90(3). 202–209. 47 indexed citations
10.
Gharagozloo, Marjan, Behjat Moayedi, Maryam Zakerinia, et al.. (2009). Combined therapy of silymarin and desferrioxamine in patients with β‐thalassemia major: a randomized double‐blind clinical trial. Fundamental and Clinical Pharmacology. 23(3). 359–365. 46 indexed citations
12.
Gharagozloo, Marjan, et al.. (2008). Premature senescence of T lymphocytes from patients with β-thalassemia major. Immunology Letters. 122(1). 84–88. 17 indexed citations
13.
Gharagozloo, Marjan, et al.. (2006). Effects of silymarin on the proliferation and glutathione levels of peripheral blood mononuclear cells from β-thalassemia major patients. International Immunopharmacology. 6(8). 1305–1310. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026